### PART B - FEE(S) TRANSMITTAL

send this form, together with applicable fee(s), to: Mail Complete and

AUG 0 2 2004

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEB and PUBLICATION FHE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as maintenance fee notifications.

The property of the patents o

23914

7590

05/14/2004

STEPHEN B. DAVIS BRISTOL-MYERS SQUIBB COMPANY PATENT DEPARTMENT P O BOX 4000 PRINCETON, NJ 08543-4000

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.

Stephen C. D'Amico (Depositor's name) (Signature) スーロシ (Date

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 10/029,347 CONFIRMATION NO. 12/20/2001 John N. Feder

TITLE OF INVENTION: NOVEL HUMAN LEUCINE-RICH REPEAT CONTAINING PROTEIN EXPRESSED PREDOMINATELY IN SMALL INTESTINE, HLRRSII

nonprovisional			FEE	bury to		
	NO	<del></del>		PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
	140		0	\$300	\$1630	08/16/2004
EXAMINER NASHED, NASHAAT T		ART U	TIF	CLASS-SUBCLASS	7	00/10/2004
		1652		435-196000	j	
<ol> <li>Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).</li> <li>Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.</li> <li>"Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.</li> </ol>			agents Offinn (have agent) an attorneys will be pri	or printing on the patent front page, list (1) the as of up to 3 registered patent attorneys or is OR, alternatively, (2) the name of a single (having as a member a registered attorney or ) and the names of up to 2 registered patent beys or agents. If no name is listed, no name of printed.		
3. ASSIGNEE NAME AND RE PLEASE NOTE: Unless an a been previously submitted to (A) NAME OF ASSIGNEE	SIDENCE DATA TO BI ussignce is identified bold the USPTO or is being st	w, no assignee da ibmitted under sep	ita will appea arate cover. (	(print or type) on the patent, Inclusion of ass Completion of this form is NOT R: (CITY and STATE OR COU	rignee data is only appropriate a substitute for filing an assign	e when an assignment h

Bristol-Myers Squibb Company

Princeton, New Jersey

USA

Please check the appropriate assignee category or categories (will not be printed on the patent); O individual O corporation or other private group entity O government 4a. The following fee(s) are enclosed: 4b. Payment of Fee(s): XIssue Fee ☐ A check in the amount of the fee(s) is enclosed. APublication Fee Payment by credit card. Form PTO-2038 is attached. Advance Order - # of Copies 10 The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number \_\_\_\_\_\_\_ 19-3880 \_\_\_\_\_\_ (enclose an extra copy of this form). Director for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.

(Authorized Signature) Reg. #46,652 (Date) NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

interest as shown by the records of the United States Patent and Trademark United.

This collection of information is required by 37 CPR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CPR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

08/02/2004 TBESHAH2 00000023 193880 10029347

01 FC:1501 02 FC:1504 300.00 DA 03 FC:8001 30.00 DA

BEST AVAILABLE COPY

TRANSMIT THIS FORM WITH FEE(S)

PTOL-85 (Rev. 11/03) Approved for use through 04/30/2004.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE OMB 0651-0033



# Bristol-Myers Squibb Company

Worldwide Medicines Group P.O. Box 4000 Princeton, NJ 08543-4000

DATE: 8-2-04

### FACSIMILE TRANSMITTAL COVER SHEET

TO:

Issue Fee Branch

FAX:

1-703-746-4000

# OF PAGES:

3 (INCLUDING FAX TRANSMITTAL SHEET)

FROM:

Joyce Whitlow

FAX #:

(609) 252-4526

PHONE #:

(609) 252-3597

RE:

U.S. Appln. Serial No.: 10/029,347

Attorney Docket No. D0066 NP

## CERTIFICATE OF TRANSMISSION VIA FACSIMILE

I hereby certify that this correspondence 1) Issue Fee Transmittal (1 page) and 2) "Fee Addresss" Indication Form (1 page) is being transmitted to the Patent and Trademark Office fax number 703-746-4000 on

Stephen C. D'Amico, Depositor

THE INFORMATION CONTAINED IN THIS FAX MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE RECIPIENT(S) NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

## BEST AVAILABLE COPY